
ORAGENICS INC
100
Oragenics has made notable progress in its Phase 2a clinical trials for ONP-002, activating multiple sites and dosing patients. The company has established manufacturing partnerships and continues to present its concussion treatment advancements at industry events.
- Oragenics activated a third site for Phase 2a trials of ONP-002 in treating concussions, with data anticipated by Q4 2026 [N1].
- The company advanced its Phase 2a trial of ONP-002 for concussion treatment, indicating ongoing clinical progress [N2].
- Oragenics dosed the first patient in the Phase 2a trial for ONP-002 targeting brain injury [N3].
- Phase 2a trial operations for ONP-002 were initiated, with positive market reaction noted [N4].
- Oragenics partnered with Sterling for U.S.-based manufacturing of ONP-002 to support clinical and potential commercial supply [N5].
- The company presented ONP-002 at the 2025 BIO International Convention and attended the 42nd Annual National Neurotrauma Society Symposium to advance scientific engagement [N6].
- Oragenics submitted an Investigator's Brochure for Phase II clinical trial of ONP-002 in Australia for mild traumatic brain injury [N8].
- The company presented at the 15th Annual Traumatic Brain Injury Conference on advances in mild traumatic brain injury detection and management [N7].
Oragenics Inc operates in the biopharmaceutical sector with a focus on developing novel drug candidates, particularly in neurology. Its lead product candidate, ONP-002, is being developed for the treatment of concussions and mild traumatic brain injury. The company does not manufacture its products internally but relies on partnerships for manufacturing and clinical trial operations. Oragenics has advanced ONP-002 into Phase 2a clinical trials with multiple active sites and has engaged in collaborations to support regulatory filings and trial design. The company has historically incurred net losses and negative cash flows, with a substantial accumulated deficit. It has raised capital through public offerings of convertible preferred stock and maintains liquidity through cash, cash equivalents, and short-term investments. Oragenics is listed on the NYSE American but currently faces compliance challenges related to stockholders' equity requirements. The company continues to explore strategic acquisitions and partnerships to enhance its pipeline and operations.
Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice. Oragenics Inc is a biopharmaceutical company focused on developing novel therapeutics, primarily advancing ONP-002 for concussion and brain injury treatment. The company is conducting Phase 2a clinical trials with multiple activated sites and has partnered for manufacturing and regulatory support. Oragenics has incurred significant net losses and has a going concern warning due to recurring losses and liquidity needs. As of September 30, 2026, it held approximately $2.2 million in cash and $4.0 million in short-term investments, with a current ratio of 1.83. The company faces risks related to capital raising, dilution from preferred stock anti-dilution provisions, and regulatory and clinical development uncertainties.
Oragenics has demonstrated progress in advancing ONP-002 through Phase 2a clinical trials with multiple activated sites and has established manufacturing partnerships in the U.S. The company has engaged in collaborations to support regulatory readiness and clinical trial design, indicating active development efforts. Its recent capital raises provide liquidity to support ongoing operations. Presentations at industry conferences and submission of clinical trial documentation reflect efforts to build scientific and commercial awareness. These factors collectively indicate a focused approach to advancing its lead neurology asset.
Oragenics faces significant risks including recurring net losses, liquidity constraints, and a going concern warning from auditors. The company must raise additional capital to continue clinical development and operations, with existing anti-dilution provisions on preferred stock potentially increasing shareholder dilution. Compliance challenges with NYSE American listing standards pose risks to its market presence. The early stage of clinical development and reliance on external partners for manufacturing and regulatory processes add operational risks. Failure to secure sufficient funding or regulatory approvals could materially impact the company's viability.
Oragenics' moat is primarily based on its proprietary drug candidate ONP-002 targeting concussion and brain injury, a therapeutic area with significant unmet medical needs. The company's advancement into Phase 2a clinical trials and partnerships for manufacturing and regulatory support contribute to its development capabilities. However, as a clinical-stage biopharmaceutical company without commercial products, its competitive advantage depends on successful clinical development, regulatory approvals, and the ability to secure strategic collaborations or licensing agreements. The company's reliance on external manufacturers and the early stage of its product pipeline limit its current moat.
• Capital Raising and Dilution Risk: Oragenics requires additional capital to fund clinical trials and operations. The Series H Convertible Preferred Stock includes anti-dilution provisions that have lowered the conversion price, increasing potential dilution to common shareholders. Difficulty in raising capital on favorable terms could impair development efforts.
• Going Concern and Liquidity Risk: The company has incurred significant losses and negative cash flows, with a going concern warning from auditors. Liquidity depends on successful capital raises and managing expenditures, with risks of operational curtailment if funding is insufficient.
• Regulatory and Clinical Development Risk: Advancement of ONP-002 depends on successful clinical trials and regulatory approvals. Delays or failures in these processes could adversely affect the company's development timeline and financial position.
• Listing Compliance Risk: Oragenics is currently non-compliant with NYSE American listing standards related to stockholders' equity and has a plan period until February 2028 to regain compliance. Failure to comply could result in delisting, affecting market liquidity and investor confidence.
• Operational and Partnership Risks: The company relies on external partners for manufacturing and clinical trial operations. Disruptions or inability of partners to meet demand could impact development progress. Strategic acquisitions and partnerships carry integration and execution risks.
Business trends: Continued advancement of ONP-002 through Phase 2a clinical trials with multiple activated sites and regulatory engagement.
Execution milestones: Completion of Phase 2a trials, data readouts by Q4 2026, and securing manufacturing and regulatory partnerships.
Key risks: Capital raising challenges with dilution risk, ongoing liquidity constraints, regulatory approval uncertainties, and NYSE American listing compliance.
Very high visibility
Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).
- Oragenics Inc is a biopharmaceutical company focused on developing novel product candidates, primarily in neurology.
- The company is advancing ONP-002, a drug candidate for concussion and brain injury treatment, currently in Phase 2a clinical trials.
- Oragenics does not manufacture its drug candidates but partners with manufacturers such as Sterling for U.S.-based production of ONP-002.
- The company has activated multiple clinical trial sites for ONP-002, including a third site for Phase 2a trials as of July 2026.
- Oragenics has engaged in partnerships to support FDA IND readiness and clinical trial design for its concussion program.
- The company has paused other programs such as lantibiotics and COVID-19 vaccine pending financing and developments, focusing resources on ONP-002.
- Recent capital raises include a $16.5 million public offering of Series H Convertible Preferred Stock and warrants in July 2025.
- The company has incurred significant net losses and negative cash flows historically and as of September 30, 2026, reported a net loss of approximately $2.6 million for the quarter.
- As of September 30, 2026, Oragenics had cash and cash equivalents of about $2.2 million and short-term investments of $4.0 million, with a current ratio of 1.83 and a cash ratio of 3.46.
- The company has substantial accumulated deficits and a full valuation allowance on deferred tax assets as of December 31, 2025.
- Oragenics received a going concern warning from its auditor due to recurring losses and liquidity needs.
- The company is listed on the NYSE American but received a notice of non-compliance with listing standards related to stockholders' equity and has a plan period through February 2028 to regain compliance.
- Oragenics' Series H Preferred Stock contains anti-dilution provisions that have adjusted the conversion price to $1.00 per share as of March 2026, potentially increasing dilution risk.
- The company has ongoing risks related to raising additional capital, potential dilution, and the ability to continue clinical development and operations.
- Oragenics has presented and plans to present ONP-002 at various industry conferences and symposiums to advance awareness and partnerships.
- The company has submitted an Investigator's Brochure for Phase II clinical trial of ONP-002 in Australia for mild traumatic brain injury.
- Oragenics has announced interim CEO appointment and strategic progress updates in early 2025.
- The company has explored strategic acquisitions and licensing opportunities but has paused some negotiations as of mid-2026.
Generated 2026-11-13
- S1
- S2
- S1 | 2026-03-16 | 10-K
- S2 | 2026-11-12 | 10-Q
- N1 | 2026-07-08 | www.nasdaq.com | Oragenics Activates Third Site For Phase 2a Of ONP-002 In Treating Concussions, Data By Q4 '26 | https://www.nasdaq.com/articles/oragenics-activates-third-site-phase-2a-onp-002-treating-concussions-data-q4-26
- N2 | 2026-04-21 | www.nasdaq.com | Oragenics Advances Phase IIa Trial Of ONP-002 For Concussion | https://www.nasdaq.com/articles/oragenics-advances-phase-iia-trial-onp-002-concussion
- N3 | 2026-04-14 | www.nasdaq.com | Oragenics Doses First Patient In Phase 2a Trial For Brain Injury Drug ONP-002 | https://www.nasdaq.com/articles/oragenics-doses-first-patient-phase-2a-trial-brain-injury-drug-onp-002
- N4 | 2026-03-12 | www.nasdaq.com | Oragenics Kick Off Phase IIa Trial Operations For ONP-002; Stock Up | https://www.nasdaq.com/articles/oragenics-kick-phase-iia-trial-operations-onp-002-stock
- N5 | 2025-07-16 | www.nasdaq.com | Oragenics Partners With Sterling For U.S.-Based Manufacturing Of Concussion Drug ONP-002 | https://www.nasdaq.com/articles/oragenics-partners-sterling-us-based-manufacturing-concussion-drug-onp-002
- N6 | 2025-06-10 | www.nasdaq.com | Oragenics, Inc. to Present ONP-002 at 2025 BIO International Convention and Attend 42nd Annual National Neurotrauma Society Symposium | https://www.nasdaq.com/articles/oragenics-inc-present-onp-002-2025-bio-international-convention-and-attend-42nd-annual
- N7 | 2025-04-23 | www.nasdaq.com | Oragenics, Inc. to Present at the 15th Annual Traumatic Brain Injury Conference on Advances in mTBI Detection and Management | https://www.nasdaq.com/articles/oragenics-inc-present-15th-annual-traumatic-brain-injury-conference-advances-mtbi
- N8 | 2025-03-06 | www.nasdaq.com | Oragenics, Inc. Submits Investigator's Brochure for Phase II Clinical Trial of ONP-002 in Australia for Mild Traumatic Brain Injury | https://www.nasdaq.com/articles/oragenics-inc-submits-investigators-brochure-phase-ii-clinical-trial-onp-002-australia
This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Generated by Valye SEC Pipeline Engine
.gif)


